1,417,914
Participants
Start Date
March 31, 2014
Primary Completion Date
April 30, 2015
Study Completion Date
April 30, 2015
DPP-4 inhibitors
Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
GLP-1 analogs
Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace
Insulins
Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
Biguanides
Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Sulfonylureas
Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Thiazolidinediones
Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Alpha-glucosidase inhibitors
Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Meglitinides
Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal
Drug Safety and Effectiveness Network, Canada
OTHER
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Canadian Network for Observational Drug Effect Studies, CNODES
OTHER